UPDATE: RBC Capital Upgrades Seagen (SGEN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Seagen Statement on Outcome of Daiichi Sankyo Arbitration
August 12, 2022 1:14 PM EDTBOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (Daiichi Sankyo) relating to the parties 2008 collaboration agreement for the use of Seagens antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.
While we are disappointed with the arbitration decision, it was important for us to pursue this legal action, said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical... More
